XIENCE Sierra: Specifically Designed for Success in CTO

With its true center tip and the lowest crossing profile of any drug-eluting stent,1 XIENCE Sierra is specifically designed for patients undergoing chronic total occlusion (CTO) procedures. Moreover, XIENCE is the only CTO indicated DES and demonstrates unrivaled safety in this complex case type.

Tip Specifically Designed for CTOs

Tip Specifically Designed for CTOs

Lowest Crossing Profile of Any DES1

Lowest Crossing Profile of Any DES1

Slim Flex Technology

The new XIENCE Sierra Stent Design has Slim Flex Technology that enables an ultra-low crossing profile.

XIENCE Sierra: The Only CTO-Indicated Drug-Eluting Stent

XIENCE Sierra is the only stent indicated for CTO patients, backed by exceptional safety outcomes:

  • ARC* definite/probable ST at 3 years: 1.4%2
  • Definite ST events beyond 30 days: 0%2   

XIENCE Sierra: The Only CTO-Indicated Drug-Eluting Stent

XIENCE Sierra is the only stent indicated for CTO patients, backed by exceptional safety outcomes:

  • ARC* definite/probable ST at 3 years: 1.4%2
  • Definite ST events beyond 30 days: 0%2   

Unrivaled Safety in CTO Procedures

In the all-CTO PRISON IV trial, XIENCE outperformed Orsiro in CTO lesions, as Orsiro failed to demonstrate non-inferiority compared to XIENCE.3

Unrivaled Safety in CTO Procedures

In the all-CTO PRISON IV trial, XIENCE outperformed Orsiro in CTO lesions, as Orsiro failed to demonstrate non-inferiority compared to XIENCE.3

“We chose the most reputable stent, . . .  XIENCE, to challenge the novel Orsiro sirolimus-eluting stent [SES] in this complex lesion subset. . . . This trial failed to show non-inferiority of the SES. . . . Furthermore, the rate of binary restenosis was statistically significantly higher with the SES [Orsiro].”   

— Koen Teeuwen, MD, PRISON IV Trial3

AP2945977-WBU Rev. A

* Academic Research Consortium (ARC)

  1. Comparative claim refers to major drug-eluting stent manufacturers in U.S. market, including Medinol. Test performed by and data on file at Abbott. Crossing profile data refers to 3.0 mm diameter and 18-20 mm lengths.
  2. Kandzari D, et al. "Safety and Effectiveness of XIENCE Stents in Chronic Total Occlusion Revascularization: 3 Year Results from the EXPERT CTO Multicenter Clinical Trial" CTO Summit 2017.
  3. Teeuwen K, et al. PRISON IV Trial. JACC Cardiovasc Interv. 2017;10:133-143. doi: 10.1016/j.jcin.2016.10.017.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?
Important safety information